Mauro Bologna

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5414000/publications.pdf

Version: 2024-02-01

68 papers	2,691 citations	196777 29 h-index	223390 49 g-index
69 all docs	69 docs citations	69 times ranked	3684 citing authors

#	Article	IF	Citations
1	Psychoneuroendocrinoimmunology-based meditation (PNEIMED) training reduces salivary cortisol under basal and stressful conditions in healthy university students: Results of a randomized controlled study. Explore: the Journal of Science and Healing, 2020, 16, 189-198.	0.4	17
2	Immunobiologia vaccinale: antigeni, anticorpi e memoria immunitaria. Pnei Review, 2018, , 7-17.	0.1	0
3	Leptin contributes to long-term stabilization of HIF-1Î± in cancer cells subjected to oxygen limiting conditions. Cancer Letters, 2016, 376, 1-9.	3.2	20
4	Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer, 2014, 14, 154.	1.1	92
5	Biological Agents and Bioterrorism. NATO Science for Peace and Security Series A: Chemistry and Biology, 2014, , 1-10.	0.5	2
6	Immunological Defence Mechanisms Against Biological Agents. NATO Science for Peace and Security Series A: Chemistry and Biology, 2014, , 11-16.	0.5	1
7	Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs. Journal of Bone and Mineral Research, 2012, 27, 2387-2398.	3.1	24
8	Biomarkers in Prostate Cancer. , 2012, , 355-380.		4
9	Tissue print of prostate biopsy: a novel tool in the diagnostic procedure of prostate cancer. Diagnostic Pathology, 2011, 6, 34.	0.9	10
10	Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5928-5933.	1.0	48
11	EphA2 Induces Metastatic Growth Regulating Amoeboid Motility and Clonogenic Potential in Prostate Carcinoma Cells. Molecular Cancer Research, 2011, 9, 149-160.	1.5	63
12	New pyrazoloâ€[3,4â€•d]â€pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells. FASEB Journal, 2010, 24, 2881-2892.	0.2	26
13	Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines. Gynecologic Oncology, 2010, 119, 557-563.	0.6	21
14	Receptor Activator of NF-ÎºB Ligand Enhances Breast Cancerâ€"Induced Osteolytic Lesions through Upregulation of Extracellular Matrix Metalloproteinase Inducer/CD147. Cancer Research, 2010, 70, 6150-6160.	0.4	54
15	Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocrine-Related Cancer, 2009, 16, 401-413.	1.6	63
16	Her2 crosstalks with TrkA in a subset of prostate cancer cells: Rationale for a guided dual treatment. Prostate, 2009, 69, 337-345.	1.2	9
17	Indolyl-pyrrolone as a new scaffold for Pim1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1512-1516.	1.0	27
18	Bicalutamide Demonstrates Biologic Effectiveness in Prostate Cancer Cell Lines and Tumor Primary Cultures Irrespective of Her2/neu Expression Levels. Urology, 2009, 74, 452-457.	0.5	5

#	Article	IF	Citations
19	Kinase-Dependent and -Independent Roles of EphA2 in the Regulation of Prostate Cancer Invasion and Metastasis. American Journal of Pathology, 2009, 174, 1492-1503.	1.9	96
20	Neuroendocrine transdifferentiation induced by VPA is mediated by PPARÎ³ activation and confers resistance to antiblastic therapy in prostate carcinoma. Prostate, 2008, 68, 588-598.	1.2	10
21	Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Prostate, 2008, 68, 793-801.	1.2	31
22	Akt downâ€•modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate, 2008, 68, 965-974.	1.2	29
23	Effects of Dutasteride on Prostate Carcinoma Primary Cultures: A Comparative Study With Finasteride and MK386. Journal of Urology, 2008, 180, 367-372.	0.2	18
24	Antiproliferative and proapoptotic activities of new pyrazolo[3,4â€•d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. FASEB Journal, 2008, 22, 1560-1571.	0.2	60
25	Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells. Endocrine-Related Cancer, 2008, 15, 91-100.	1.6	24
26	Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. Endocrine-Related Cancer, 2007, 14, 601-611.	1.6	29
27	Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells. Oncology Reports, 2007, 18, 503.	1.2	1
28	Surgical and Biologic Outcomes After Neoadjuvant Bicalutamide Treatment in Prostate Cancer. Urology, 2007, 70, 728-733.	0.5	35
29	Identification of a Novel Pyrazolo[3,4-d]pyrimidine Able To Inhibit Cell Proliferation of a Human Osteogenic Sarcoma in Vitro and in a Xenograft Model in Mice. Journal of Medicinal Chemistry, 2007, 50, 5579-5588.	2.9	79
30	In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma. Prostate, 2007, 67, 1255-1264.	1.2	20
31	Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells. Oncology Reports, 2007, 18, 503-11.	1.2	11
32	Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. European Journal of Cancer, 2006, 42, 2838-2845.	1.3	62
33	Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. Anti-Cancer Drugs, 2006, 17, 1141-1150.	0.7	33
34	Inhibition of Protein Kinase c-Src Reduces the Incidence of Breast Cancer Metastases and Increases Survival in Mice: Implications for Therapy. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 161-172.	1.3	126
35	Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocrine-Related Cancer, 2006, 13, 197-210.	1.6	79
36	Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells. Journal of Cancer Research and Clinical Oncology, 2005, 131, 243-254.	1.2	8

#	Article	IF	Citations
37	Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. Thrombosis and Haemostasis, 2005, 93, 964-975.	1.8	93
38	Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples. International Journal of Oncology, 2005, 26, 1353.	1.4	3
39	Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples. International Journal of Oncology, 2005, 26, 1353-62.	1.4	2
40	Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia. Journal of Cancer Research and Clinical Oncology, 2004, 130, 217-221.	1.2	24
41	Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate, 2004, 59, 157-166.	1.2	56
42	Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effectsin vitro and inhibit spontaneous metastases of human melanoma in mice. International Journal of Cancer, 2004, 110, 125-133.	2.3	42
43	An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. International Journal of Cancer, 2004, 112, 909-919.	2.3	108
44	Evaluation of metastatic potential in prostate carcinoma: an in vivo model. International Journal of Oncology, 2004, 25, 1713-20.	1.4	12
45	Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. Journal of Cancer Research and Clinical Oncology, 2003, 129, 165-174.	1.2	71
46	Characterization of Prostate Cancer DU145 Cells Expressing the Recombinant Androgen Receptor. Oncology Research, 2003, 14, 101-112.	0.6	24
47	Osteopontin Modulates Prostate Carcinoma Invasive Capacity through RGD-Dependent Upregulation of Plasminogen Activators. Biological Chemistry, 2002, 383, 229-234.	1.2	33
48	Bombesin-Dependent Pro-MMP-9 Activation in Prostatic Cancer Cells Requires Î²1 Integrin Engagement. Experimental Cell Research, 2002, 280, 1-11.	1.2	22
49	Type 5 phosphodiesterase expression in the human vagina. Urology, 2002, 60, 191-195.	0.5	136
50	Bicalutamide dose-dependently inhibits proliferation in human prostatic carcinoma cell lines and primary cultures. Anticancer Research, 2002, 22, 2917-22.	0.5	7
51	Agar specimen orientation technique revisited: A simple and effective method in histopathology. Annals of Diagnostic Pathology, 2001, 5, 107-109.	0.6	12
52	Osteoblast-derived TGF-Î²1 modulates matrix degrading protease expression and activity in prostate cancer cells. International Journal of Cancer, 2000, 85, 407-415.	2.3	59
53	Osteoblast-derived TGF?-1 modulates matrix degrading protease expression and activity in prostate cancer cells. , 2000, 86, 888-888.		16
54	Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clinical and Experimental Metastasis, 2000, 18, 163-170.	1.7	74

#	Article	IF	Citations
55	Osteoblast conditioned media contain TGF-?1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. , 1999, 81, 395-403.		78
56	Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clinical and Experimental Metastasis, 1998, 16, 513-528.	1.7	82
57	In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. , 1998, 75, 418-431.		54
58	Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. International Journal of Cancer, 1996, 69, 386-393.	2.3	50
59	Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. , 1996, 69, 386.		4
60	Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology, 1995, 45, 282-290.	0.5	61
61	Early Diagnosis of Prostatic Carcinoma May Be Achieved through in vitro Culture of Tumor Cells Harvested by Prostatic Massage. European Urology, 1993, 24, 148-155.	0.9	10
62	Bombesin stimulates growth of human prostatic cancer cellsin vitro. Cancer, 1990, 63, 1714-1720.	2.0	199
63	Short-Term Tissue Culture of Prostatic Carcinoma Samples Provides Useful Biological Parameters Related to Patient Prognosis. European Urology, 1988, 15, 243-247.	0.9	9
64	Early Diagnosis of Prostatic Carcinoma Based on in vitro Culture of Viable Tumor Cells Harvested by Prostatic Massage. European Urology, 1988, 14, 474-476.	0.9	15
65	A method for double immunofluorescent staining by the indirect procedure with antibodies of the same isotype. Journal of Immunological Methods, 1986, 86, 151-153.	0.6	7
66	High-performance liquid chromatographic procedure for the quantitation of norfloxacin in urine, serum and tissues. Biomedical Applications, 1984, 309, 177-182.	1.7	28
67	BACTERICIDAL INTRAPROSTATIC CONCENTRATIONS OF NORFLOXACIN. Lancet, The, 1983, 322, 280.	6.3	19
68	Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients. Oncology Reports, 0, , .	1.2	5